178 related articles for article (PubMed ID: 15921858)
1. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
Wu T
Biochim Biophys Acta; 2005 Jul; 1755(2):135-50. PubMed ID: 15921858
[TBL] [Abstract][Full Text] [Related]
2. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells.
Wu T; Han C; Lunz JG; Michalopoulos G; Shelhamer JH; Demetris AJ
Hepatology; 2002 Aug; 36(2):363-73. PubMed ID: 12143044
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 in hepatocellular carcinoma.
Wu T
Cancer Treat Rev; 2006 Feb; 32(1):28-44. PubMed ID: 16337744
[TBL] [Abstract][Full Text] [Related]
4. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells.
Nzeako UC; Guicciardi ME; Yoon JH; Bronk SF; Gores GJ
Hepatology; 2002 Mar; 35(3):552-9. PubMed ID: 11870367
[TBL] [Abstract][Full Text] [Related]
5. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
Endo K; Yoon BI; Pairojkul C; Demetris AJ; Sirica AE
Hepatology; 2002 Aug; 36(2):439-50. PubMed ID: 12143054
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids.
Lim K; Han C; Xu L; Isse K; Demetris AJ; Wu T
Cancer Res; 2008 Jan; 68(2):553-60. PubMed ID: 18199552
[TBL] [Abstract][Full Text] [Related]
7. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.
Sirica AE
Hepatology; 2005 Jan; 41(1):5-15. PubMed ID: 15690474
[TBL] [Abstract][Full Text] [Related]
8. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
9. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.
Sirica AE; Lai GH; Zhang Z
J Gastroenterol Hepatol; 2001 Apr; 16(4):363-72. PubMed ID: 11357901
[TBL] [Abstract][Full Text] [Related]
10. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.
Yoon JH; Gwak GY; Lee HS; Bronk SF; Werneburg NW; Gores GJ
J Hepatol; 2004 Nov; 41(5):808-14. PubMed ID: 15519654
[TBL] [Abstract][Full Text] [Related]
11. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
13. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
Sirica AE
World J Gastroenterol; 2008 Dec; 14(46):7033-58. PubMed ID: 19084911
[TBL] [Abstract][Full Text] [Related]
14. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Chun KS; Surh YJ
Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
Hayashi N; Yamamoto H; Hiraoka N; Dono K; Ito Y; Okami J; Kondo M; Nagano H; Umeshita K; Sakon M; Matsuura N; Nakamori S; Monden M
Hepatology; 2001 Oct; 34(4 Pt 1):638-50. PubMed ID: 11584358
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets.
Sirica AE; Lai GH; Endo K; Zhang Z; Yoon BI
Semin Liver Dis; 2002 Aug; 22(3):303-13. PubMed ID: 12360423
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cyclo-oxygenase-2.
Stack E; DuBois RN
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):787-800. PubMed ID: 11566041
[TBL] [Abstract][Full Text] [Related]
19. Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.
Wu GS; Wang JH; Liu ZR; Zou SQ
Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):429-33. PubMed ID: 14607721
[TBL] [Abstract][Full Text] [Related]
20. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.
Chariyalertsak S; Sirikulchayanonta V; Mayer D; Kopp-Schneider A; Fürstenberger G; Marks F; Müller-Decker K
Gut; 2001 Jan; 48(1):80-6. PubMed ID: 11115827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
